2 not yet recruiting, 1 recruiting, 1 terminated, 1 unknown. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Not yet recruiting 2, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Relapsed or Refractory B-cell Lymphoma: new trials by email Literature Review of Relapsed or Refractory B-cell Lymphoma trials Research Report on Relapsed or Refractory B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas Glofitamab, Epcoritamab, Polatuzumab Vedotin - Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Relapsed or Refractory B-cell Lymphoma | Phase 2 | Recruiting | National Research Center for Hematology, Russia | 40 | 2026-09-01 | 2026-10-20 |
| Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma Pirtobrutinib, Second Infusion of Commercial Anti-CD19 CAR-T Cells - Relapsed or Refractory B-cell Lymphoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 20 | 2026-06-01 | 2026-06-03 |
| Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL SR-GDP - Relapsed or Refractory B-cell Lymphoma | Phase 2 | Not yet recruiting | Ruijin Hospital | 50 | 2023-10-30 | 2023-11-07 |
| A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma MS-553 - Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Terminated | MingSight Pharmaceuticals, Inc | 8 | 2023-02-06 | 2024-07-18 |
| CART-19 Cells for R/R B-cell Lymphoma CART-19 cells - Relapsed or Refractory B-cell Lymphoma | Phase 2 / Phase 3 | Unknown | Fujian Medical University | 20 | 2016-01-01 | 2018-01-05 |
Lymphoma, B-Cell (5) · Recurrence (5) · Lymphoma, Large B-Cell, Diffuse (2) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1)
Disease Attributes (5) · Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoma, Non-Hodgkin (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Lymphoma (4) · Chronic Disease (1) · Hematologic Diseases (1) · Leukemia (1)
gemcitabine-oxaliplatin regimen (1) · glofitamab (1) · obinutuzumab (1) · pirtobrutinib (1) · polatuzumab vedotin (1)
Fujian Medical University (1) · MingSight Pharmaceuticals, Inc (1) · National Research Center for Hematology, Russia (1) · Ruijin Hospital (1) · Sun Yat-sen University (1)
China (4) · Russia (1)